Novel tumor-infiltrating lymphocytes therapy in solid tumors: latest updates from 2025 ASCO annual meeting [0.03%]
2025年ASCO年会固体制剂肿瘤浸润淋巴细胞治疗最新进展
Yanan Ma,Xuan Su,Huijing Feng
Yanan Ma
Tumor-infiltrating lymphocyte (TIL) therapy, a highly promising form of adoptive cell therapy (ACT), has demonstrated success in treating advanced melanoma. Notably, innovative TIL-based monotherapies and combination regimens have provided ...
FGL1-mediated lymph node metastasis in stage T1 non-small cell lung cancer: therapeutic targeting [0.03%]
FGRL1介导的T1期非小细胞肺癌淋巴结转移及其治疗靶向性研究
Xi-Yang Tang,Run-Ze Zhang,Zhi-Bo Feng et al.
Xi-Yang Tang et al.
Background: Approximately 30% of patients with stage T1 non-small cell lung cancer (NSCLC) have mediastinal (N2) lymph node metastasis; however, the underlying mechanism remains unclear. ...
Transforming cancer immunotherapy: integration of distinct immune-based approaches as redefined dual immunotherapy with potential third-sensitizer [0.03%]
重塑癌症免疫治疗：作为重新定义的双重免疫治疗集成不同基于免疫的方法及潜在的第三增敏疗法
Yuqian Wang,Cheng Jiang,Huiling Zhou et al.
Yuqian Wang et al.
This review introduces a paradigm-shifting concept of Dual Distinct Immunotherapy (DDI), which strategically integrates two distinct immunotherapeutic modalities to overcome the limitations of current monotherapies and dual immune checkpoin...
Tumor-priming CD8+ natural killer T-like cells as an efficient novel cell therapy for relapsed/refractory multiple myeloma [0.03%]
肿瘤预激CD8⁺自然杀伤T类细胞作为治疗复发/难治性多发性骨髓瘤的一种有效新型的细胞疗法
Juheon Lee,Eunjeong Choi,Bohwa Han et al.
Juheon Lee et al.
Background: Relapsed and refractory multiple myeloma (RRMM) remains a major clinical challenge, as most patients eventually relapse following standard treatments and are left with limited therapeutic options. Although b-c...
Precise regulation of RAS-Mediated PI3Kα activation: therapeutic potential of BBO-10203 in cancer treatment [0.03%]
精准调控RAS介导的PI3Kα激活：BBO-10203在癌症治疗中的潜在疗效
Ziyi Fan,Erqing Tan,Bin Song
Ziyi Fan
In recent years, the Phosphoinositide-3-Kinase α (PI3Kα) signaling pathway has been increasingly recognized as a critical driver of tumorigenesis, particularly in breast cancer drug resistance and other solid tumors. Although conventional...
Overall survival of recurrent/metastatic head & neck squamous cell carcinoma patients progressing after ≥ 1 line of systemic therapy, treated with MVX-ONCO-1, a novel, first in class cell encapsulation-based immunotherapy: results of SAKK 11/16, a phase IIa trial [0.03%]
MVX-ONCO-1治疗复发/转移性头颈部鳞状细胞癌患者（至少一线系统治疗后进展）的总生存期：SAKK 11/16二期a阶段试验结果，一种新型首创新药，基于细胞封装的免疫疗法
Eugenio Fernandez,Rémi Vernet,Muriel Urwyler et al.
Eugenio Fernandez et al.
Background: Over the past two decades, most cancer vaccines have failed to be developed clinically. The lack of efficient priming with specific tumor antigens and/or weak adjuvants may explain this poor success rate. MVX-...
IL-7-PD-L1 nano-antibody mediated "zipper" effect augments the tumoricidal activity of tumor-infiltrating lymphocytes [0.03%]
白细胞介素7程序性死亡配体1纳米抗体介导的“拉链”效应增强肿瘤浸润淋巴细胞的杀瘤活性
Zhongjie Yu,Zhen Guo,Bin Jiang et al.
Zhongjie Yu et al.
Cancer represents a pressing global health concern, characterized by a substantial number of unmet clinical needs. Cell therapy has emerged as a promising and efficacious approach for cancer treatment, particularly tumor-infiltrating lympho...
Extracellular matrix stiffness reduces DNA 6 ma level to facilitate colorectal cancer progression via disrupting P53 binding to CDKN1A promoter [0.03%]
细胞外基质刚度通过破坏P53与CDKN1A启动子的结合降低DNA 6mA水平以促进结直肠癌进展
Si-An Xie,Xue Li,Min-Yue Yin et al.
Si-An Xie et al.
The extracellular matrix (ECM) forms the primary scaffold of the tumor microenvironment, with matrix stiffness serving as a critical physical cue that modulates cancer progression. However, the impact of matrix stiffness on colorectal cance...
Improving CAR-T cell function through a targeted cytokine delivery system utilizing car target-modified extracellular vesicles [0.03%]
利用car靶向修饰的细胞外囊泡的靶向细胞因子递送系统改善car-t细胞功能
Yuanyuan Zhang,Meijuan Huang,Shujia Zhang et al.
Yuanyuan Zhang et al.
Chimeric antigen receptor (CAR)-T-cell therapy has achieved remarkable clinical success in the treatment of B-cell malignancies; however, its efficacy can be limited by poor T-cell persistence and insufficient antitumor activity in certain ...
The anticancer thiosemicarbazone triapine exerts immune-enhancing activities via immunogenic cell death induction and FAS upregulation [0.03%]
三氮唑羧酰胺类抗肿瘤药物Triapine通过诱导免疫源性细胞死亡和上调FAS发挥增强免疫力的作用
Bianca Stiller,Alessia Stefanelli,Hemma Schueffl et al.
Bianca Stiller et al.
The anticancer thiosemicarbazone Triapine is currently in a phase III clinical trial in combination with radiation therapy and cisplatin. Noteworthy, while radiotherapy induces an immune-activating cell death, so called immunogenic cell dea...